Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer

• Published in: The Journal of pathology Vol. 261; no. 2; pp. 156 - 168
• Main Authors: Tsoi, Ho, Lok, Johann, Man, Ellen PS, Cheng, Cheuk‐Nam, Leung, Man‐Hong, You, Chan‐Ping, Chan, Sum‐Yin, Chan, Wing‐Lok, Khoo, Ui‐Soon
• Format: Journal Article
• Language: English
• Published: Chichester, UK John Wiley & Sons, Ltd 01.10.2023; Wiley Subscription Services, Inc
• Subjects: Alternative splicing; Anastrozole; androgen receptor; Androgen receptors; Androgens; AR antagonist; Aromatase; aromatase inhibitor resistance; BQ323636.1; Breast cancer; Cell proliferation; Endocrine therapy; Estrogen receptors; Menopause; oestrogen receptor; Patients; androgen receptor; BQ323636.1; AR antagonist; aromatase inhibitor resistance; breast cancer; oestrogen receptor; anastrozole
• ISSN: 0022-3417; 1096-9896; 1096-9896
• DOI: 10.1002/path.6157

Aromatase inhibitors (Ais) are used as adjuvant endocrine therapy for oestrogen receptor‐positive (ER+ve) post‐menopausal breast cancer patients. Ais, by inhibiting the enzyme aromatase, block the conversion of androgen to oestrogen, reducing oestrogen levels. Resistance to Ais limits their clinical...